Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)

Kestra Medical reports 66% Q4 revenue growth and $137 million FY27 revenue guidance

Positive Impact 4 of 5 earnings Written later

Kestra Medical reported fiscal fourth-quarter 2026 revenue of $28.6 million, up 66%, and gave fiscal 2027 revenue guidance of $137 million, 44% above fiscal 2026. On July 10, 2026, it also entered a five-year senior secured term loan facility of up to $200.0 million, with $75.0 million funded at closing and used to repay its prior loan, which matters to shareholders because it adds debt secured by substantially all company assets.

Key points

  • Fiscal 4Q26 revenue was $28.6 million, up 66%, and gross margin was 54.8% versus 44.3% a year earlier.
  • FY27 revenue guidance is $137 million, compared with FY26 revenue of $95.1 million.
  • GAAP net loss was $38.8 million for the quarter versus $51.1 million a year earlier, but $131.6 million for the full year versus $113.8 million in FY25.
  • The July 10, 2026 loan has a $200.0 million facility, matures July 10, 2031, and requires at least $20.0 million in minimum liquidity.

The filing

CompanyKESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)
Form8-K, current report
Filed with the SECJul 14, 2026, 4:08 PM ET
Accession number0001193125-26-303169

Items reported: 1.01 Material Definitive Agreement1.02 Termination of Material Agreement2.02 Results of Operations2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.